Oncoshot partners up with Mitsui & Co. Ltd. on Asia-US clinical data collaboration built on IHH's clinical data
Updated: Oct 1

We're proud to share that Oncoshot — a Milltrust Ventures portfolio company — has signed a service agreement with Mitsui & Co., Ltd. to deploy its AI platform across IHH Healthcare's hospital network. IHH runs 89 hospitals across 10 countries under brands including Gleneagles, Mount Elizabeth Hospitals, Singapore, Parkway Shenton Pte Ltd, and Fortis Healthcare — and Mitsui, its largest shareholder, is bringing Oncoshot in to standardise oncology data, shorten clinical trial timelines, and support international cancer research across a patient population that spans the Asia-Pacific.
What makes Oncoshot's approach work is that the data never leaves the hospital. Its platform anonymises and structures clinical records — EMRs, lab results, real-world care data — into research-ready datasets, entirely within each institution's own environment. Privacy compliance isn't a workaround; it's built into the architecture.
This is exactly the kind of company Milltrust Ventures backs: deep science, a clear commercial pathway, and the potential to reshape how an entire industry operates — years before it becomes obvious to the rest of the market.
Interested in how we identify and invest in transformative early-stage health companies — or how we construct bespoke private market portfolios for private wealth clients? Reach out to Sean Ang 洪旻彬, Director of Milltrust Ventures, or drop us a note at mv@milltrust.com.
Check out the announcement: https://lnkd.in/g6BzP5sm



